Curis (CRIS) Net Shares Issued and Repurchased (2012 - 2016)
Curis' (CRIS) quarterly Net Shares Issued and Repurchased came in at $2.3 million in Q1 2016, up 92.43% on a YoY basis from $1.2 million in Q2 2015, and down 29.74% quarter-over-quarter from $3.2 million in Q4 2015.
Analysis
Curis (CRIS) Net Shares Issued and Repurchased (2012 - 2016) Analysis & Trends
Curis (CRIS) has reported Net Shares Issued and Repurchased for 5 consecutive years, with $2.3 million the latest figure, recorded in Q1 2016.
- For the quarter ending Q1 2016, Net Shares Issued and Repurchased rose 92.43% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2016 stood at $2.3 million (up 92.43% YoY), and the FY2015 full-year result was $3.2 million, up 41.87% from the prior year.
- Net Shares Issued and Repurchased eased to $2.3 million in Q1 2016 per CRIS's latest filing, from $3.2 million in the prior quarter.
- Across five years, Net Shares Issued and Repurchased topped out at $3.2 million in Q4 2015 and bottomed at $1.2 million in Q1 2015.
- Historically, Net Shares Issued and Repurchased has averaged $2.0 million across 5 years, with a median of $2.0 million in 2012.
- The sharpest annual moves came in 2014 and 2016: Net Shares Issued and Repurchased retreated 20.46% in 2014, then surged 92.43% in 2016.
- Over 5 years, Net Shares Issued and Repurchased stood at $1.7 million in 2012, then jumped by 73.18% to $2.9 million in 2013, then retreated by 20.46% to $2.3 million in 2014, then surged by 41.87% to $3.2 million in 2015, then dropped by 29.74% to $2.3 million in 2016.
- According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $2.3 million, $3.2 million, and $1.2 million for Q1 2016, Q4 2015, and Q1 2015 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Curis | 2.57 Mn | -3.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2016 | 2.27 Mn |
| Dec 31, 2015 | 3.23 Mn |
| Mar 31, 2015 | 1.18 Mn |
| Dec 31, 2014 | 2.28 Mn |
| Mar 31, 2014 | 1.36 Mn |
| Dec 31, 2013 | 2.86 Mn |
| Mar 31, 2013 | 1.25 Mn |
| Dec 31, 2012 | 1.65 Mn |